A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus

NCT03962010 on ClinicalTrials.gov · last registry update 2019-05-23

78 participants. Its estimated completion date, 1 June 2022, has passed with no update to the record. Primary outcome, as filed: Change in HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Genexine, Inc.
Sponsor type: Industry
Enrollment: 78
Started: 2019-06-01
Primary completion: 2022-06-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.